MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Consolidator ... Mass Market Scale-up, Global Reach, Public Capital
Consolidators: BioPharmaceuticals
Bausch Health Companies Inc. (NASDAQ: BHC)
Organization & Developments: Bausch
Parents
Bausch Health Companies Inc. (NASDAQ: BHC)
Children
*Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology.
2018: Bausch Health Stock Is Approaching A Breakout — Here's Why_www.investors.com
2020: Why Investors Should Buy More Bausch Health Stock
2021: Bausch Health: Buy Ahead Of Bausch + Lomb Spin-Off
2022: Bausch + Lomb and Clearside Biomedical’s Xipere is a corticosteroid injection that is used to treat macular edema.
2022: Bausch Health Companies Inc. 2022 Q3 - Results - Earnings Call Presentation_seekingalpha.com
2024: 2 Red Alerts On Bausch Health Companies
2024: Bausch + Lomb And Bausch Health: Some Incremental Progress As We Wait For Sale News
2024: Bausch Health: Bankruptcy Rumors Scotched For Now, But May Persis
2024: Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely
2025: Bausch Health Q4 Earnings Recap (Reiterating Buy Rating)
2025: Bausch Health: Repricing Potential Driven By Deleveraging
Jumps
*Key People: Bausch
Finance & Acquisition: Bausch